The Journal of Pediatrics
Volume 152, Issue 1 , Pages 101-105 , January 2008

Folate Pathway Genetic Polymorphisms are Related to Attention Disorders in Childhood Leukemia Survivors

  • Kevin R. Krull, PhD

      Affiliations

    • Learning Support Center for Child Psychology, Texas Children’s Hospital, Houston, TX
    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Corresponding Author InformationReprint requests: Kevin R. Krull, PhD, Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, 332 N. Lauderdale St, MS 735, Memphis, TN 38105-2794.
    • ,
  • Pim Brouwers, PhD

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • Division of AIDS & Health and Behavior Research, National Institute of Mental Health, Rockville, MD
    • ,
  • Neelam Jain, PhD

      Affiliations

    • Learning Support Center for Child Psychology, Texas Children’s Hospital, Houston, TX
    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • ,
  • Linna Zhang, MD

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • ,
  • Lisa Bomgaars, MD

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • ,
  • ZoAnn Dreyer, MD

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • ,
  • Donald Mahoney, MD

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • ,
  • Sarah Bottomley, MN, CPNP

      Affiliations

    • Texas Children’s Cancer Center, Houston, TX
    • ,
  • M. Fatih Okcu, MD, MPH

      Affiliations

    • Department of Pediatrics, Baylor College of Medicine, Houston, TX
    • Texas Children’s Cancer Center, Houston, TX
    • Childhood Cancer Epidemiology and Prevention Center, Houston, TX.

Received 7 November 2006 ,Revised 24 April 2007 ,Accepted 29 May 2007.

References 

  1. Hewitt M, Weiner SL, Simone JV. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: National Academy of Sciences; 2003;
  2. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000;15:603–630
  3. Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol. 1991;9:1348–1356
  4. Montour-Proulx I, Kuehn SM, Keene DL, Barrowman NJ, Hsu E, Matzinger MA, et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol. 2005;20:129–133
  5. Espy KA, Moore IM, Kaufmann PM, Kramer JH, Matthay K, Hutter JJ. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol. 2001;26:1–9
  6. Kaemingk KL, Carey ME, Moore IM, Herzer M, Hutter JJ. Math weaknesses in survivors of acute lymphoblastic leukemia compared with healthy children. Child Neuropsychol. 2004;10:14–23
  7. Brown RT, Madan-Swain A, Pais R, Lambert RG, Sexson S, Ragab A. Chemotherapy for acute lymphocytic leukemia: cognitive and academic sequelae. J Pediatr. 1992;121:885–889
  8. Carey ME, Hockenberry MJ, Moore IM, Hutter JJ, Krull KR, Pasvogel A, et al. Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. J Pediatr Psychol. 2007;32:189–193
  9. Paakko E, Harila-Saari A, Vanionpaa L, Himanen S, Pyhtinen J, Lanning M. White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. Med Pediatr Oncol. 2000;35:456–461
  10. Waber DP, Carpentieri SC, Klar N, Silverman LB, Schwenn M, Hurwitz CA, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000;22:206–213
  11. Wolkowitz OM, Lupien SJ, Bigler E, Levin RB, Canick J. The “steroid dementia syndrome”: an unrecognized complication of glucocorticoid treatment. Ann N Y Acad Sci. 2004;1032:191–194
  12. Brouwers P. Study of the neurobehavioral consequences of childhood cancer: entering the genomic era?. Commentary J Pediatr Psychol. 2005;30:79–84
  13. Kingma A, Van Dommelen RI, Mooyaart EL, Wilmink JT, Deelman BG, Kamps WA. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol. 2002;24:106–114
  14. Rodgers J, Marckus R, Kearns P, Windebank K. Attentional ability among survivors of leukaemia treated without cranial irradiation. Arch Dis Child. 2003;88:147–150
  15. Miketova P, Kaemingk K, Hockenberry M, Pasvogel A, Hutter J, Krull K, et al. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol Res Nurs. 2005;6:187–195
  16. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther. 1985;28:77–102
  17. Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single-nucleotide polymorphisms: a meta-analysis. J Hum Genet. 2003;48:1–7
  18. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613–622
  19. Gadow KD, Sprafkin J. Child Symptom Inventory. Stony Brook, NY: Checkmate Plus; 1997;
  20. Sprafkin J, Gadow KD, Salisbury H, Schneider J, Loney J. Further evidence of reliability and validity of the Child Symptom Inventory 4 parent checklist in clinically referred boys. J Clin Child Adolesc Psychol. 2002;31:513–524
  21. Ferguson GA. Statistical Analysis in Psychology & Education. 4th edition. New York: McGraw-Hill; 1976;
  22. Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, et al. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia. Clin Cancer Res. 2000;6:3123–3130
  23. Krull KR, Jain N, Brouwers P, Law R, Bottomley S, Dreyer Z. Childhood leukemia survivors: patterns of ADHD symptomology. J Int Neuropsychol Soc. 2003;9:261
  24. Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Primeau M, et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics. 2005;6:293–302
  25. Robien K, Boynton A, Ulrich CM. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics. 2005;6:673–689
  26. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  27. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151:862–877
  28. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol. 2003;157:571–582
  29. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenom. 2001;1:189–201
  30. Gimpel GA, Kuhn BR. Maternal report of attention deficit hyperactivity disorder symptoms in preschool children. Child Care Health Dev. 2000;26:163–179
  31. Byrne JM, Bawden HN, Beattie TL, DeWolfe NA. Preschoolers classified as having attention-deficit hyperactivity disorder (ADHD): DSM-IV symptom endorsement pattern. J Child Neurol. 2000;15:533–538
  32. Maitland-van der Zee AH, de Boer A, Leufkens HG. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol. 2000;410:121–130
  33. Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol. 2000;40:930–938
  34. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99–108

 No author reports any conflict of interest associated with this study.

PII: S0022-3476(07)00551-3

doi: 10.1016/j.jpeds.2007.05.047

The Journal of Pediatrics
Volume 152, Issue 1 , Pages 101-105 , January 2008

Article Tools

* Image Usage & Resolution